A framework for in silico prediction of drug safety and efficacy in populations of human cardiac cell models
Virtual Assay V4 brings electrophysiology and contractility together in a single, validated, human-based mechanistic framework — enabling early, quantitative prediction of both electrical and mechanical cardiac risk.
Applications: Drug discovery, drug development
| Features | Benefits |
|---|---|
| Simultaneous prediction of proarrhythmic and inotropic risk | More informed portfolio decisions |
| Quantitatively validated contractility prediction (86–95% agreement benchmarks) | Smarter experimentation |
| Human-specific modelling eliminating species translation issues | Reduced reliance on ex vivo animal testing through human-based modelling |
| Mechanistic, auditable drug–channel–tension traceability | Earlier de-risking |
| Population-level risk stratification |
Available For
- Co-development
- Consulting
- Licensing